$VKTX
Viking Therapeutics, Inc.

2019 Q3 Form 10-Q Financial Statement

#000156459019028043 Filed on August 01, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2019 Q2 2018 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.160M $2.240M $1.700M
YoY Change 26.32% 31.76% 33.86%
% of Gross Profit
Research & Development $5.280M $7.333M $5.221M
YoY Change -7.21% 40.45% 40.5%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $7.440M $9.569M $6.925M
YoY Change 0.68% 38.18% 38.97%
Operating Profit -$9.569M -$6.925M
YoY Change 38.18% 38.97%
Interest Expense $1.742M $1.900M $392.0K
YoY Change 111.41% 384.69% -39300.0%
% of Operating Profit
Other Income/Expense, Net $1.708M $0.00 $253.0K
YoY Change 115.11% -100.0% -233.86%
Pretax Income -$5.730M -$7.670M -$6.670M
YoY Change -13.18% 14.99% 29.01%
Income Tax
% Of Pretax Income
Net Earnings -$5.731M -$7.674M -$6.672M
YoY Change -13.17% 15.02% 29.0%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$79.54K -$106.6K -$126.4K
COMMON SHARES
Basic Shares Outstanding 72.21M 52.77M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2019 Q2 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $288.1M $292.6M $142.2M
YoY Change -5.29% 105.79% 1075.21%
Cash & Equivalents $30.95M $19.12M $34.61M
Short-Term Investments $257.1M $273.5M $107.6M
Other Short-Term Assets $1.200M $1.000M $2.100M
YoY Change -52.0% -52.38% -4.55%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $289.3M $293.6M $144.3M
YoY Change -5.66% 103.55% 908.8%
LONG-TERM ASSETS
Property, Plant & Equipment $700.0K $700.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $100.0K $200.0K
YoY Change 0.0% -50.0% 100.0%
Total Long-Term Assets $866.0K $849.0K $210.0K
YoY Change 333.0% 304.29%
TOTAL ASSETS
Total Short-Term Assets $289.3M $293.6M $144.3M
Total Long-Term Assets $866.0K $849.0K $210.0K
Total Assets $290.1M $294.5M $144.5M
YoY Change -5.44% 103.85% 910.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.095M $1.870M $1.493M
YoY Change 74.58% 25.25% 14.85%
Accrued Expenses $4.100M $3.800M $2.600M
YoY Change 17.14% 46.15% 4.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $6.192M $5.626M $4.105M
YoY Change 31.74% 37.05% -46.69%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $400.0K $500.0K
YoY Change
Total Long-Term Liabilities $438.0K $513.0K $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.192M $5.626M $4.105M
Total Long-Term Liabilities $438.0K $513.0K $0.00
Total Liabilities $6.630M $6.139M $4.105M
YoY Change 41.06% 49.55% -46.92%
SHAREHOLDERS EQUITY
Retained Earnings -$121.2M -$115.5M -$91.08M
YoY Change 26.83% 28.88%
Common Stock $404.6M $403.6M $231.6M
YoY Change 74.29% 199.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $283.5M $288.4M $140.4M
YoY Change
Total Liabilities & Shareholders Equity $290.1M $294.5M $144.5M
YoY Change -5.44% 103.85% 908.79%

Cashflow Statement

Concept 2019 Q3 2019 Q2 2018 Q2
OPERATING ACTIVITIES
Net Income -$5.731M -$7.674M -$6.672M
YoY Change -13.17% 15.02% 29.0%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$3.400M -$6.460M -$5.270M
YoY Change -38.29% 22.58% 25.48%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $15.15M $10.98M -$66.62M
YoY Change -155.92% -116.48% 8551.95%
Cash From Investing Activities $15.15M $10.98M -$66.62M
YoY Change -155.92% -116.48% 8551.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 70.00K 260.0K 70.15M
YoY Change -99.96% -99.63% 1649.38%
NET CHANGE
Cash From Operating Activities -3.400M -6.460M -5.270M
Cash From Investing Activities 15.15M 10.98M -66.62M
Cash From Financing Activities 70.00K 260.0K 70.15M
Net Change In Cash 11.82M 4.780M -1.740M
YoY Change -91.24% -374.71% 81.25%
FREE CASH FLOW
Cash From Operating Activities -$3.400M -$6.460M -$5.270M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Shell Company
EntityShellCompany
false
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
72210630
dei Entity File Number
EntityFileNumber
001-37355
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
461073877
dei Entity Address Address Line1
EntityAddressAddressLine1
12340 El Camino Real
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 250
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
California
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
704-4660
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19123000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24779000
CY2019Q2 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
273513000
CY2018Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
276741000
CY2019Q2 vktx Prepaid Clinical Trial And Preclinical Study Costs
PrepaidClinicalTrialAndPreclinicalStudyCosts
343000
CY2018Q4 vktx Prepaid Clinical Trial And Preclinical Study Costs
PrepaidClinicalTrialAndPreclinicalStudyCosts
335000
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
665000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
278000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
293644000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
302133000
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
730000
CY2019Q2 vktx Deferred Public Offering And Other Financing Costs Noncurrent
DeferredPublicOfferingAndOtherFinancingCostsNoncurrent
90000
CY2018Q4 vktx Deferred Public Offering And Other Financing Costs Noncurrent
DeferredPublicOfferingAndOtherFinancingCostsNoncurrent
150000
CY2019Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
29000
CY2018Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
29000
CY2019Q2 us-gaap Assets
Assets
294493000
CY2018Q4 us-gaap Assets
Assets
302312000
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1870000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
959000
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3468000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3591000
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
288000
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5626000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4550000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
12000
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
513000
CY2019Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
513000
CY2018Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
12000
CY2019Q2 us-gaap Liabilities
Liabilities
6139000
CY2018Q4 us-gaap Liabilities
Liabilities
4562000
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2019Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
403630000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
401090000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-115516000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102918000
CY2019Q2 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
239000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-423000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
288354000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
297750000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
294493000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
302312000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72173489
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71742043
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
72173489
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71742043
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7333000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5221000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11828000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8264000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2236000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1704000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4547000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3466000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
9569000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
6925000
us-gaap Operating Expenses
OperatingExpenses
16375000
us-gaap Operating Expenses
OperatingExpenses
11730000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9569000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6925000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16375000
CY2019Q2 vktx Change In Fair Value Of Debt Conversion Features
ChangeInFairValueOfDebtConversionFeatures
0
CY2018Q2 vktx Change In Fair Value Of Debt Conversion Features
ChangeInFairValueOfDebtConversionFeatures
37000
vktx Change In Fair Value Of Debt Conversion Features
ChangeInFairValueOfDebtConversionFeatures
0
CY2019Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
404000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11730000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7386000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6710000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11936000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10350000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
71921239
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52767111
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
71838647
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
48730381
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
884000
CY2019Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
107000
CY2019Q2 vktx Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
175000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
297750000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
1834000
us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
171000
vktx Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
535000
CY2018Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
72632000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
531000
CY2018Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
242000
CY2018Q2 vktx Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
1381000
CY2018Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
140363000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
1142000
us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
313000
vktx Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
4826000
vktx Stock Issued During Period Value Sale Of Stock Net Of Issuance Costs
StockIssuedDuringPeriodValueSaleOfStockNetOfIssuanceCosts
130968000
us-gaap Profit Loss
ProfitLoss
-12598000
us-gaap Profit Loss
ProfitLoss
-10223000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
138000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-149000
vktx Amortization Of Non Cash Clinical Trial Costs
AmortizationOfNonCashClinicalTrialCosts
140000
vktx Amortization Of Non Cash Clinical Trial Costs
AmortizationOfNonCashClinicalTrialCosts
477000
us-gaap Share Based Compensation
ShareBasedCompensation
1956000
us-gaap Share Based Compensation
ShareBasedCompensation
1241000
vktx Realized Gain Loss On Investmens
RealizedGainLossOnInvestmens
2000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
535000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1396000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
910000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
592000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
116000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9611000
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
288354000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
113707000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10573000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
182884000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
186254000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
17455000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3370000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-96252000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
131402000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
266000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
3833000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
122000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
99000
vktx Proceeds From Warrant And Option Exercises And Stock Issuance Under Employee Stock Purchase Plan
ProceedsFromWarrantAndOptionExercisesAndStockIssuanceUnderEmployeeStockPurchasePlan
707000
vktx Proceeds From Warrant And Option Exercises And Stock Issuance Under Employee Stock Purchase Plan
ProceedsFromWarrantAndOptionExercisesAndStockIssuanceUnderEmployeeStockPurchasePlan
5243000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
585000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
132447000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5656000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
25622000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8988000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34610000
us-gaap Interest Paid Net
InterestPaidNet
81000
vktx Unpaid Deferred Initial Public Offering And Other Financing Costs
UnpaidDeferredInitialPublicOfferingAndOtherFinancingCosts
309000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
416000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
276741000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements relate to determining the fair value of the debt conversion feature liability through May 21, 2018 and accounting for an operating lease and certain commitments. Actual results could differ from those estimates.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents and marketable securities. The Company maintains deposits in federally insured depository institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9223697
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10086061
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q2 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-09-24
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
CY2019Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
0
us-gaap Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
Three months or less
CY2019Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
72104334
CY2018Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
52973371
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
72021742
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
48955952
CY2019Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
183095
CY2018Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
206260
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
183095
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
225571
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2018 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2019Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
273273000
CY2018Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
181
CY2019Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
261000
CY2018Q4 vktx Available For Sale Securities In Unrealized Gain Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableForSaleSecuritiesInUnrealizedGainPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
3
CY2019Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
21000
CY2019Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
273513000
CY2019Q2 vktx Available For Sale Securities In Unrealized Gain Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableForSaleSecuritiesInUnrealizedGainPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
136
CY2019Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
36
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
277156000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2019Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
290940000
CY2018Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
300441000
vktx Operating Lease Number Of Leases
OperatingLeaseNumberOfLeases
1
vktx Opeating Lease Expiration Period
OpeatingLeaseExpirationPeriod
2022-01
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0600
CY2019Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
77000
us-gaap Operating Lease Expense
OperatingLeaseExpense
154000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
163000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
333000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
343000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
29000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
868000
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
67000
CY2014Q1 us-gaap Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance
DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
1000000
CY2014Q1 us-gaap Deferred Compensation Arrangement With Individual Exercise Price
DeferredCompensationArrangementWithIndividualExercisePrice
0.01
CY2014Q1 vktx Number Of Tranches
NumberOfTranches
2
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
168000
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
633810
CY2015Q2 vktx Shares Repurchase Price Per Share
SharesRepurchasePricePerShare
0.00001
CY2015Q2 us-gaap Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
366190
CY2015Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
62000
CY2018 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
CY2019Q2 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
9568
CY2018Q2 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
72597
CY2018Q2 us-gaap Share Based Compensation
ShareBasedCompensation
630000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2014047
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
636287
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
36937
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
13988
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2599409
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1221405
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.72
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.97
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.84
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.07
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.76
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.75
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y2M15D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
198000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
9703000
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5813000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
105000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
239000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.50
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7834
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y25D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0246
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
vktx Description Of Warrant
DescriptionOfWarrant
The warrant was exercisable for cash or on a cashless basis at a per share exercise price equal to $10.00 commencing on April 28, 2016, one year following the date of the prospectus filed with the SEC relating to the IPO, and expiring on April 28, 2020. The warrant was exercised in full during the year ended December 31, 2018. The warrant also provided for registration rights upon request, under certain circumstances. The piggyback registration right provided in connection with the warrant was to terminate on April 28, 2022.
vktx Warrant Expiration Date
WarrantExpirationDate
2022-04-28
vktx Initial Public Offering Expiration Date
InitialPublicOfferingExpirationDate
2020-04-28
CY2016Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7500000
CY2016Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
7500000
CY2016Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.25
CY2016Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.50
vktx Class Of Warrants Or Rights Expiry Date
ClassOfWarrantsOrRightsExpiryDate
2021-04-13
CY2016Q2 us-gaap Share Price
SharePrice
0.01
CY2019Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
4168238
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
116603
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
356363
vktx Operating Lease Option To Extend Term
OperatingLeaseOptionToExtendTerm
P3Y
CY2019Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
77000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
154000
CY2018Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
63000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
125000
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
163000
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
333000
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
343000
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
29000
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
868000

Files In Submission

Name View Source Status
0001564590-19-028043-index-headers.html Edgar Link pending
0001564590-19-028043-index.html Edgar Link pending
0001564590-19-028043.txt Edgar Link pending
0001564590-19-028043-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vktx-10q_20190630.htm Edgar Link pending
vktx-20190630.xml Edgar Link completed
vktx-20190630.xsd Edgar Link pending
vktx-20190630_cal.xml Edgar Link unprocessable
vktx-20190630_def.xml Edgar Link unprocessable
vktx-20190630_lab.xml Edgar Link unprocessable
vktx-20190630_pre.xml Edgar Link unprocessable
vktx-ex311_8.htm Edgar Link pending
vktx-ex312_6.htm Edgar Link pending
vktx-ex321_7.htm Edgar Link pending